Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b
- Resource Type
- Article
- Source
- In
Leukemia Research January 2024 136 - Subject
- Language
- ISSN
- 0145-2126